TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21692783

Group type: EXPERIMENTAL
Intervention: Jordan Power electric toothbrush
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Panbehriz Classic manual toothbrush
Number of subjects: 45

Group type: COMPARATOR
Intervention: Jordan toothbrush
Number of subjects: 45
Study: 19234829

Group type: EXPERIMENTAL
Intervention: Individualized recruitment maneuver (RM) with pressure equal to 15 ml x real body weight/Cdyn + PEEP for 15 s
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control RM with pressure of 20 cmH2O for 25 s
Number of subjects: 28
Study: 16410482

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (10-week duration)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unsupervised exercise program (1-week supervised instruction followed by 9-week unsupervised home program)
Number of subjects: 72
Study: 15277416

Group type: EXPERIMENTAL
Intervention: GLP-1 (4.8 pmol x kg(‐1) x min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-mg tablet of Actos)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination therapy with GLP-1 and pioglitazone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline therapy
Number of subjects: 8
Study: 11582613

Group type: EXPERIMENTAL
Intervention: Slick Tracy Home Team Program (adapted version)
Number of subjects: 1212
Study: 9161093

Group type: EXPERIMENTAL
Intervention: Interactive videodisc instruction (IVDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lecture/demonstration
Number of subjects: 0
Study: 8487231

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 dilution of epinephrine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 45
Study: 2891740

Group type: EXPERIMENTAL
Intervention: Metipranolol drops
Number of subjects: 26

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 26
Study: 31548150

Group type: EXPERIMENTAL
Intervention: Open 'crown' type repair (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Percutaneous Bunnell type repair (group B)
Number of subjects: 100
Study: 30013913

Group type: EXPERIMENTAL
Intervention: Isoleucine supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Leucine supplementation
Number of subjects: 27
Study: 28498185

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control (no CQI intervention)
Number of subjects: 511
Study: 25496354

Group type: EXPERIMENTAL
Intervention: Sheath drainage system
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Body-worn urinal (BWU)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Penile clamp
Number of subjects: 56

Group type: COMPARATOR
Intervention: Absorbent pads
Number of subjects: 56
Study: 23954500

Group type: EXPERIMENTAL
Intervention: 6.5mg prasterone (DHEA) administered intravaginally daily
Number of subjects: 0
Study: 21364916

Group type: EXPERIMENTAL
Intervention: Model‐free and model‐based connectivity analysis for moral sensitivity task
Number of subjects: 0
Study: 18090394

Group type: EXPERIMENTAL
Intervention: NNRTI
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: PI
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: NNRTI plus PI (three-class)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Differential adherence (any antiretroviral medication)
Number of subjects: 1379
Study: 16647628

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 12597957

Group type: EXPERIMENTAL
Intervention: Brachytherapy (palladium-103 or iodine-125)
Number of subjects: 215
Study: 10774095

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate (200 or 400 micrograms every 12 hours)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg every 21 days)
Number of subjects: 15
Study: 8923554

Group type: EXPERIMENTAL
Intervention: Visual search task with Kanizsa-type subjective contours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual search task without subjective contours
Number of subjects: 0
Study: 1374040

Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng infused into the graft over 2 min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3912026

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg (given in two or four equally divided daily doses)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ibuprofen (twice daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ibuprofen (four times daily)
Number of subjects: 144
Study: 31301627

Group type: EXPERIMENTAL
Intervention: Sunlight plus conventional vitamin D supplement (400IU/d)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Sunlight exposure (7-14 h/week) plus conventional vitamin D supplement (400IU/d)
Number of subjects: 349
Study: 28707255

Group type: EXPERIMENTAL
Intervention: Ellips FX phaco handpiece
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard phaco handpiece
Number of subjects: 160
Study: 25521163

Group type: EXPERIMENTAL
Intervention: ISQ values measured at 0, 2, 4, 8, 12, 16, and 20 weeks postoperation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ISQ values compared among groups at all observed time points
Number of subjects: 39
Study: 24813646

Group type: EXPERIMENTAL
Intervention: 120 mg ATP daily for 4 weeks
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 22818021

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (2.5 mg twice daily in selected patients)
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Aspirin 81 to 324 mg daily
Number of subjects: 1697
Study: 20603700

Group type: EXPERIMENTAL
Intervention: Wheelchair rugby training (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 17630253

Group type: EXPERIMENTAL
Intervention: Prodromal symptoms
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Overall prodrome score
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses including other potential predictors
Number of subjects: 339
Study: 16307657

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg per week
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Etanercept (both dosages)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 12114351

Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus zafirlukast 20 mg bid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus theophylline 200 to 300 mg bid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beclomethasone 400 microg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus zafirlukast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus theophylline
Number of subjects: 24
Study: 10439754

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.1% ropivacaine with 1 microgram/mL sufentanil (R + S)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural infusion of 0.1% ropivacaine without sufentanil (R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (R + S and R)
Number of subjects: 30
Study: 8560534

Group type: EXPERIMENTAL
Intervention: Ivermectin (5 doses distributed every 6 months)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control (untreated village)
Number of subjects: 3000
Study: 2518436

Group type: EXPERIMENTAL
Intervention: Different surgical techniques employed in pancreatic allograft
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various procedures concerning the site of implantation and treatment of exocrine function
Number of subjects: 0
Study: 61224

Group type: COMPARATOR
Intervention: Tolmetin sodium (800-1600 mg daily for 12 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolmetin sodium (400-2400 mg daily for 2 years)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31842133

Group type: EXPERIMENTAL
Intervention: WBV + BFR
Number of subjects: 50

Group type: COMPARATOR
Intervention: WBV only
Number of subjects: 50
Study: 31176298

Group type: EXPERIMENTAL
Intervention: GLP-1 analog exenatide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 28244804

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing delivered in community pharmacies as a standalone service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing integrated into medication therapy management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacogenetic testing delivery
Number of subjects: 0
Study: 25367713

Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy
Number of subjects: 0
Study: 23559420

Group type: EXPERIMENTAL
Intervention: Repeat PSA test or prostate biopsy within 9 months
Number of subjects: 6294

Group type: EXPERIMENTAL
Intervention: Non-Hispanic black men aged <65 years
Number of subjects: 6294

Group type: COMPARATOR
Intervention: Older men (≥65 years)
Number of subjects: 6294
Study: 20980486

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Bifidobacterium breve and Lactobacillus casei
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (human milk without probiotics)
Number of subjects: 231
Study: 19807901

Group type: EXPERIMENTAL
Intervention: Community health workers using a 20-sign algorithm to classify newborn illnesses.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Community health workers recognizing signs and symptoms of newborn illnesses.
Number of subjects: 288
Study: 16456408

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor + ranitidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Proton pump inhibitor + placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Number of subjects: 18
Study: 15173081

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 402
Study: 12207595

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isotretinoin gel 0.05%
Number of subjects: 80
Study: 9707349

Group type: EXPERIMENTAL
Intervention: Epogam (evening primrose oil) - 6 capsules in the morning and 6 capsules in the evening
Number of subjects: 6
Study: 7611748

Group type: EXPERIMENTAL
Intervention: Sandwiches chosen based on liking and variety-seeking tendency
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Variety-seeking tendency
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Choice frequencies of sandwich fillings
Number of subjects: 26
Study: 2248110

Group type: EXPERIMENTAL
Intervention: Cue exposure and response prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 359254

Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone 3-times daily
Number of subjects: 31
Study: 31234904

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) probiotic intervention for 4 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 50
Study: 27073000

Group type: EXPERIMENTAL
Intervention: HR-ADM plus standard of care (SOC) applied weekly for up to 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HR-ADM plus SOC
Number of subjects: 40

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 40
Study: 26030112

Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 24151264

Group type: COMPARATOR
Intervention: 28‐mm metal‐on‐metal uncemented total hip replacements (THRs)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Hybrid hip resurfacing (HR)
Number of subjects: 192
Study: 21188412

Group type: EXPERIMENTAL
Intervention: Hot condition (35°C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cool condition (20°C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (pre-exercise)
Number of subjects: 9
Study: 19661836

Group type: EXPERIMENTAL
Intervention: Low water content (38%, Soflens 38) non‐ionic HCLs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High water content (66%, Soflens 66) non‐ionic HCLs
Number of subjects: 16
Study: 17541827

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 0
Study: 15517057

Group type: EXPERIMENTAL
Intervention: Psychodynamic group treatment (PGT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Credible placebo control group (CPC)
Number of subjects: 30
Study: 11843242

Group type: EXPERIMENTAL
Intervention: vinorelbine-cisplatin (NVB-P)
Number of subjects: 612

Group type: COMPARATOR
Intervention: vinorelbine (NVB)
Number of subjects: 612

Group type: COMPARATOR
Intervention: vindesine-cisplatin (VDS-P)
Number of subjects: 612
Study: 9754586

Group type: EXPERIMENTAL
Intervention: Exercise performance assessment in symptomatic patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Exercise performance assessment in asymptomatic patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients
Number of subjects: 103
Study: 7918729

Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment (CGA) by geriatric nurse practitioners (GNPs) with yearly assessments, quarterly follow-up visits, and regular telephone contacts.
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment (CGA) by GNPs.
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 414
Study: 30049729

Group type: EXPERIMENTAL
Intervention: Bubble nCPAP and nebulised surfactant (200 mg/kg: poractant alfa)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bubble nCPAP alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bubble nCPAP and nebulised surfactant
Number of subjects: 64
Study: 27688002

Group type: EXPERIMENTAL
Intervention: Organized physical activity intervention (led by instructors)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-physical activity control group
Number of subjects: 108
Study: 25979614

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (250 mg weekly intramuscular injections)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 22853707

Group type: EXPERIMENTAL
Intervention: Strengths based case management
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 36
Study: 21312264

Group type: EXPERIMENTAL
Intervention: ONO-5334 50 mg twice daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg once daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg once daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 19779611

Group type: EXPERIMENTAL
Intervention: Telephone Counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual Care (brief intervention)
Number of subjects: 0
Study: 16512551

Group type: EXPERIMENTAL
Intervention: Monte Carlo-based inverse model for diffuse reflectance
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Support vector machine classification algorithm
Number of subjects: 41
Study: 12763981

Group type: EXPERIMENTAL
Intervention: 50% reduction in inhaled corticosteroid dose (stepdown)
Number of subjects: 259

Group type: COMPARATOR
Intervention: No alteration to inhaled corticosteroid dose (control)
Number of subjects: 259
Study: 10678632

Group type: EXPERIMENTAL
Intervention: 375 mg oral slow-release theophylline (250 mg if <70 kg) taken twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Matched placebo tablet taken twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both theophylline and placebo
Number of subjects: 35
Study: 9362433

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg) as a 4-hour infusion every 4 weeks for 21 cycles in addition to antimyeloma chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0
Study: 8383639

Group type: EXPERIMENTAL
Intervention: Gorging pattern (2 meals daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nibbling pattern (3 to 5 meals daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both feeding regimens (Gorging and Nibbling)
Number of subjects: 14
Study: 3535005

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily) for 6 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fundoplication surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Short-term treatment with ranitidine
Number of subjects: 31
Study: 30078745

Group type: EXPERIMENTAL
Intervention: Intervention package including concise information sheet, semi-completed forms, VSS clinic contacts, and text message reminders.
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 833

Group type: COMPARATOR
Intervention: Control group receiving publicly available leaflets about VSS
Number of subjects: 833
Study: 26812925

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 15 U/kg/leg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 10 U/kg/leg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 25316451

Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Daily emotional monitoring
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 110
Study: 22389428

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg/day) plus lifestyle counselling
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo plus lifestyle counselling
Number of subjects: 222
Study: 20187842

Group type: COMPARATOR
Intervention: DPSGC 50 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: DPSGC 25 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: DPSGC 25 mg and 50 mg
Number of subjects: 75
Study: 18270542

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 99770

Group type: COMPARATOR
Intervention: Control group (no revaccination)
Number of subjects: 99770
Study: 16274480

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg prophylactic and 4 mg postoperative IV) and Diclofenac potassium (50 mg oral before and after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac potassium (50 mg oral before and after surgery)
Number of subjects: 100
Study: 11950484

Group type: EXPERIMENTAL
Intervention: 10 mg ketanserin given as intravenous boluses every 10 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg ketanserin given as intravenous boluses every 20 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10468799

Group type: EXPERIMENTAL
Intervention: Maxacalcitol 25 microg/g
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Maxacalcitol (6, 12.5, 25, and 50 microg/g)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g
Number of subjects: 144
Study: 8678261

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.2 mg.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.1 mg.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: prochlorperazine 0.2 mg.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study: 2149047

Group type: EXPERIMENTAL
Intervention: Teicoplanin (T) 6 mg/kg/d and Fluconazole (F) 3 mg/kg/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Teicoplanin (T) 10 mg/kg/d, Ceftriaxone (C) 50 mg/kg/d, and Amikacin (A) 15 mg/kg/d
Number of subjects: 46
Study: 379841

Group type: EXPERIMENTAL
Intervention: 768 mg chlormethiazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30476343

Group type: EXPERIMENTAL
Intervention: Movement-based mind-body intervention (n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control (n = 24)
Number of subjects: 50
Study: 31597002

Group type: EXPERIMENTAL
Intervention: ATLG
Number of subjects: 1500
Study: 28724331

Group type: EXPERIMENTAL
Intervention: Balanites aegyptiaca (BE) capsules (400mg/day) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26669547

Group type: EXPERIMENTAL
Intervention: 5 or 6 mm-long implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mm-long implants
Number of subjects: 20
Study: 24424409

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg, 3-month loading phase with monthly injections, followed by a 12-month maintenance phase.
Number of subjects: 1729
Study: 22940437

Group type: EXPERIMENTAL
Intervention: EHCSS-K6 (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: EHCSS-K3 (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lark One cigarettes (1mg tar, 0.1mg nicotine, and 2.0mg CO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 128

Group type: COMPARATOR
Intervention: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Number of subjects: 128
Study: 18818045

Group type: EXPERIMENTAL
Intervention: Personal counselling intervention with the GP
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group (week 1)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Computer expert system intervention (week 2)
Number of subjects: 1260